A PYMNTS Company

US: The FTC is investigating Martin Shkreli’s previous company too

By  |  January 25, 2016

Turing Pharmaceuticals, the company previously headed by infamous “pharma bro” Martin Shkreli, is being investigated by the US Federal Trade Commission for possible antitrust violations after it jacked up the price of an AIDS drug by 5,500 percent. Under Shkreli’s leadership, Turing increased the price of Daraprim from $13.50 to $750 per pill in September last year, shortly after acquiring the rights to the medication.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Despite widespread criticism for the price hike, Shkreli said that if he could do it again, he “probably would have raised the price higher.”

    News of the investigation was revealed in a letter from Shkreli’s lawyer to the US House of Representatives’ Committee on Oversight and Government Reform, which had subpoenaed Shkreli to appear at a hearing about developments in the prescription drug market on January 26th.

    The former CEO of Turing Pharmaceuticals and KaloBios was arrested on fraud charges late last year, and in the letter, his lawyer argues that asking Shkreli to discuss the raising of drug prices would breach his constitutional right not to incriminate himself.

    Full content: The New York Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.